Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH. Here, SLC25A1 is linked to metabolic dysfunction-associated steatotic liver disease.